IBD
MCID: IRR002
MIFTS: 50

Irritable Bowel Syndrome (IBD)

Categories: Gastrointestinal diseases

Aliases & Classifications for Irritable Bowel Syndrome

MalaCards integrated aliases for Irritable Bowel Syndrome:

Name: Irritable Bowel Syndrome 12 76 37 43 44 15 63 73
Ibd 12 3
Irritable Colon 12
Psychogenic Ibs 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9778
ICD10 33 K58 K58.9 K58.0
ICD9CM 35 564.1
MeSH 44 D043183
NCIt 50 C82343
SNOMED-CT 68 10743008
KEGG 37 H01615
UMLS 73 C0022104

Summaries for Irritable Bowel Syndrome

MedlinePlus : 43 Irritable bowel syndrome (IBS) is a problem that affects the large intestine. It can cause abdominal cramping, bloating, and a change in bowel habits. Some people with the disorder have constipation. Some have diarrhea. Others go back and forth between the two. Although IBS can cause a great deal of discomfort, it does not harm the intestines. IBS is common. It affects about twice as many women as men and is most often found in people younger than 45 years. No one knows the exact cause of IBS. There is no specific test for it. Your doctor may run tests to be sure you don't have other diseases. These tests may include stool sampling tests, blood tests, and x-rays. Your doctor may also do a test called a sigmoidoscopy or colonoscopy. Most people diagnosed with IBS can control their symptoms with diet, stress management, probiotics, and medicine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Irritable Bowel Syndrome, also known as ibd, is related to isobutyryl-coa dehydrogenase deficiency and diarrhea, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Irritable Bowel Syndrome is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1). The drugs Pentoxifylline and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and brain.

Disease Ontology : 12 A syndrome that is a functional bowel disorder characterized by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits in the absence of any detectable organic cause.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn’s disease. Inflammation affects the entire digestive tract in Crohn’s disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body’s immune system.

PubMed Health : 63 About irritable bowel syndrome: The typical symptoms of irritable bowel syndrome (IBS) include abdominal pain, constipation and diarrhea. Although IBS is not dangerous, the symptoms can be very painful and bothersome. Most people who have IBS have a mild form which they can cope with quite well without getting any treatment. But some people have symptoms that are so severe they significantly affect their everyday lives and cause distress. There is no cure for IBS. But over time, many people find out what helps and what makes things worse. And there are a number of different ways to relieve the symptoms.

Wikipedia : 76 Irritable bowel syndrome (IBS) is a group of symptoms�??including abdominal pain and changes in the... more...

Related Diseases for Irritable Bowel Syndrome

Diseases related to Irritable Bowel Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 247)
# Related Disease Score Top Affiliating Genes
1 isobutyryl-coa dehydrogenase deficiency 11.9
2 diarrhea 11.6
3 gastrointestinal defects and immunodeficiency syndrome 11.6
4 interstitial cystitis 11.5
5 cholangitis, primary sclerosing 11.5
6 fecal incontinence 11.4
7 lymphoproliferative syndrome, x-linked, 2 11.3
8 inflammatory bowel disease 25, autosomal recessive 11.3
9 postural orthostatic tachycardia syndrome 11.1
10 colonic disease 11.1
11 hereditary alpha tryptasemia syndrome 11.1
12 immunodeficiency, common variable, 11 11.0
13 ileocolitis 11.0
14 constipation 10.9
15 ichthyosis bullosa of siemens 10.9
16 dyspepsia 10.7
17 inflammatory bowel disease 10.7
18 anxiety 10.6
19 colitis 10.6
20 depression 10.6
21 gastroesophageal reflux 10.5
22 celiac disease 1 10.5
23 ulcerative colitis 10.5
24 lactose intolerance 10.5
25 microscopic colitis 10.4
26 allergic hypersensitivity disease 10.4
27 fibromyalgia 10.4
28 gastroenteritis 10.3
29 food allergy 10.3
30 endometriosis 10.3
31 chronic fatigue syndrome 10.3
32 crohn's disease 10.3
33 sclerosing cholangitis 10.2
34 cholangitis 10.2
35 restless legs syndrome 10.2
36 functional diarrhea 10.2
37 prostatitis 10.2
38 panic disorder 10.2
39 giardiasis 10.2
40 diverticulitis 10.2
41 iron metabolism disease 10.2
42 methane production 10.2
43 generalized anxiety disorder 10.2
44 cystitis 10.2
45 body mass index quantitative trait locus 1 10.1
46 ischemic colitis 10.1
47 pelvic inflammatory disease 10.1
48 gastroparesis 10.1
49 dysentery 10.1
50 epilepsy 10.1

Comorbidity relations with Irritable Bowel Syndrome via Phenotypic Disease Network (PDN): (show all 26)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Anxiety
Atrophic Gastritis Bronchitis
Chronic Myocardial Ischemia Deficiency Anemia
Dependent Personality Disorder Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Generalized Anxiety Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Ischemic Heart Disease
Major Depressive Disorder Mitral Valve Disease
Osteoporosis Paralytic Ileus
Protein-Energy Malnutrition Somatization Disorder

Graphical network of the top 20 diseases related to Irritable Bowel Syndrome:



Diseases related to Irritable Bowel Syndrome

Symptoms & Phenotypes for Irritable Bowel Syndrome

UMLS symptoms related to Irritable Bowel Syndrome:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas, vomiting following gastrointestinal surgery

Drugs & Therapeutics for Irritable Bowel Syndrome

PubMedHealth treatment related to Irritable Bowel Syndrome: 63

There are a lot of different opinions about what can help relieve irritable bowel syndrome. Common recommendations include eating or avoiding certain foods and getting exercise. But most of this advice has not been tested in good-quality studies. If you ask different people who have IBS, it becomes clear that something that helps one person may end up making someone else’s symptoms worse. So it is best to try out different things and see for yourself if it helps.For example, someone who thinks that a particular type of food is making their symptoms worse can try to avoid eating it for a while. Some people have fewer symptoms if they eat their meals in smaller portions throughout the day. Keeping a diary can help you figure out whether doing specific things like exercising more or avoiding certain types of food have any effect. You can make a note of what you eat, how physically active you are, and how stressed you are over a longer period of time. It might be possible to recognize patterns after a while.There are also a number of different treatments that aim to relieve the symptoms. Because the causes of IBS are not clear, it is difficult to find suitable treatments. But research has suggested that at least some medications and treatments may help. Treatments for IBS include:Fiber supplements, for instance made from psylliumPeppermint oilProbioticsAnti-cramping medicationsMedications for constipation or diarrheaVarious medications, such as antibiotics or antidepressantsPsychological treatments, such as stress management or hypnosisBecause medications in particular can have a number of side effects and sometimes even make the symptoms worse, it is worth carefully considering the potential advantages and disadvantages of taking them.

Drugs for Irritable Bowel Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 359)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
5
Curcumin Approved, Experimental, Investigational Phase 4,Phase 2,Not Applicable 458-37-7 969516
6
Turmeric Approved, Experimental, Investigational Phase 4,Not Applicable
7
Loperamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 53179-11-6 3955
8
Metronidazole Approved Phase 4 443-48-1 4173
9
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
10
Lactulose Approved Phase 4,Phase 3,Phase 2,Not Applicable 4618-18-2 11333
11
Perphenazine Approved Phase 4 58-39-9 4748
12
Amitriptyline Approved Phase 4 50-48-6 2160
13
Simethicone Approved Phase 4,Phase 1 8050-81-5
14
Alverine Approved, Investigational Phase 4 150-59-4 3678
15
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
16
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
17
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
18
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
19
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
20
Eluxadoline Approved, Investigational Phase 4,Phase 3,Phase 2 864821-90-9
21
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
22
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
23
Pancrelipase Approved, Investigational Phase 4,Not Applicable 53608-75-6
24
Histamine Approved, Investigational Phase 4,Phase 2 51-45-6, 75614-87-8 774
25
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
26
Trimebutine Approved Phase 4,Phase 2,Phase 3 39133-31-8
27
Ondansetron Approved Phase 4,Phase 3,Phase 2,Not Applicable 99614-02-5 4595
28
Lubiprostone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136790-76-6 656719
29
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-23-7 5754
30
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-03-3
31
Montelukast Approved Phase 4 158966-92-8 5281040
32
Pantoprazole Approved Phase 4 102625-70-7 4679
33
Clarithromycin Approved Phase 4 81103-11-9 84029
34
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
35
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
36
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
37
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 77-92-9 311
38
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 1 67-97-0 5280795 6221
39
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Not Applicable 1406-16-2
40 Tiropramide Investigational Phase 4 55837-29-1 42262
41 Mosapride Investigational Phase 4,Phase 3,Phase 2 112885-41-3
42 Ramosetron Investigational Phase 4,Phase 3,Phase 2 132036-88-5
43
Maleic acid Experimental Phase 4 110-16-7 444266
44 Fenoverine Investigational Phase 4 37561-27-6
45
Daidzein Experimental Phase 4 486-66-8 5281708
46
Genistein Investigational Phase 4 446-72-0 5280961
47 Cholinergic Agents Phase 4,Phase 2,Not Applicable
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 733)
# Name Status NCT ID Phase Drugs
1 Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome Unknown status NCT02614963 Phase 4 Clostridium Butyricum;placebo
2 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
3 Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome Unknown status NCT01629212 Phase 4 Tiropramide HCl 100mg;Octylonium bromide 20mg
4 Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Unknown status NCT02728063 Phase 4
5 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
6 Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS) Unknown status NCT01542268 Phase 4 pentoxifylline;pentoxifylline placebo
7 Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome Unknown status NCT02565550 Phase 4
8 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
9 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
10 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
11 Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D Unknown status NCT01638208 Phase 4 VSL#3
12 Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy Unknown status NCT02386904 Phase 4 Phosphate Enema (Kleen® Enema)
13 Effect of Ramosetron on Bowel Motility After Gynecological Surgery Unknown status NCT02849483 Phase 4 Ramosetron;Normal saline
14 Effect of Ramosetron on Bowel Motility After Colorectal Resection Unknown status NCT01427127 Phase 4 Ramosetron
15 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
16 Improving Bowel Habits of Elderly With Probiotics and Non-probiotics Unknown status NCT02949882 Phase 4
17 Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
18 Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS) Completed NCT01404923 Phase 4 anti spasmodic agents;alverine citrate, simeticone
19 An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome Completed NCT00401258 Phase 4 duloxetine
20 Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial) Completed NCT00934973 Phase 4 mebeverine;methylcellulose;placebo
21 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
22 Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression Completed NCT01754493 Phase 4 Duloxetine
23 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
24 Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome Completed NCT01331213 Phase 4 Pregabalin;Placebo
25 Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome Completed NCT01139736 Phase 4
26 Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study Completed NCT02077699 Phase 4
27 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use Completed NCT02959983 Phase 4 Eluxadoline;Placebo
28 A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients Completed NCT01225237 Phase 4 Ramosetron;Placebo
29 Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
30 Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS) Completed NCT00693732 Phase 4 Escitalopram treatment
31 An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Completed NCT02590432 Phase 4 Linaclotide 290 micrograms;Linaclotide 145 micrograms;Linaclotide 72 micrograms
32 Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) Completed NCT01316718 Phase 4 Mesalazine;Placebo
33 A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4 Ramosetron;Placebo
34 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo
35 Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome Completed NCT01886781 Phase 4 Lactobacillus plantarum 299v;Placebo comparator
36 Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome Completed NCT00542295 Phase 4 alverine citrate and simeticone;placebo
37 Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists Completed NCT01144832 Phase 4 ebastine;placebo capsule
38 Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids Completed NCT02111603 Phase 4 Colesevelam
39 Comparative Efficacy and Safety of Fenoverine Completed NCT01507922 Phase 4 Fenoverine;Timebutine
40 Multi-strain Probiotic in the Management of IBS-D Completed NCT03251625 Phase 4 Probiotic Formula Capsule
41 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
42 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4 Tegaserod
43 Study to Assess the Effect Of Alosetron On Mucosal Blood Flow Completed NCT00370032 Phase 4 alosetron
44 EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth Completed NCT00331994 Phase 4 Bacillus clausii;Metronidazole
45 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D) Completed NCT00745004 Phase 4 Ondansetron;Placebo
46 Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea Completed NCT01667627 Phase 4
47 Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders Completed NCT02566876 Phase 4 Mixture of three Bifidobacteria
48 Mode of Action of Moviprep Completed NCT01622972 Phase 4 Polyethyleneglycol
49 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
50 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH

Search NIH Clinical Center for Irritable Bowel Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: irritable bowel syndrome

Genetic Tests for Irritable Bowel Syndrome

Anatomical Context for Irritable Bowel Syndrome

MalaCards organs/tissues related to Irritable Bowel Syndrome:

41
Colon, Testes, Brain, Small Intestine, Kidney, Liver, Heart

Publications for Irritable Bowel Syndrome

Articles related to Irritable Bowel Syndrome:

(show top 50) (show all 3022)
# Title Authors Year
1
Excluding irritable bowel syndrome in the inflammatory bowel disease patient: how far to go? ( 30407259 )
2019
2
Irritable Bowel Syndrome: What Treatments Really Work. ( 30466670 )
2019
3
Irritable bowel syndrome following Clostridium difficile infection. ( 30335629 )
2019
4
Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches. ( 30407258 )
2019
5
Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome. ( 29911328 )
2018
6
Risk of psychiatric disorders in irritable bowel syndrome-A nationwide, population-based, cohort study. ( 29920876 )
2018
7
Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. ( 29421792 )
2018
8
The gut microbiome and irritable bowel syndrome: State of art review. ( 29935865 )
2018
9
A 8-year population-based cohort study of irritable bowel syndrome in childhood with history of atopic dermatitis. ( 29374025 )
2018
10
Obesity and irritable bowel syndrome: coincidence or association? ( 29922769 )
2018
11
Prevalence of Fructose Malabsorption in Patients With Irritable Bowel Syndrome After Excluding Small Intestinal Bacterial Overgrowth. ( 29433301 )
2018
12
The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. ( 29445178 )
2018
13
Shuganyin decoction improves the intestinal barrier function in a rat model of irritable bowel syndrome induced by water-avoidance stress. ( 29434653 )
2018
14
Perceived Stress, Its Physiological Correlates, and Quality of Life in Patients With Irritable Bowel Syndrome. ( 29402137 )
2018
15
Food consumption and dietary intakes in 36,448 adults and their association with irritable bowel syndrome: Nutrinet-SantAc study. ( 29399039 )
2018
16
<i>trans</i>-Resveratrol Ameliorates Stress-Induced Irritable Bowel Syndrome-Like Behaviors by Regulation of Brain-Gut Axis. ( 29962949 )
2018
17
Irritable Bowel Syndrome with predominant diarrhea and giardiasis: is it one or the other? ( 29500067 )
2018
18
Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. ( 29956419 )
2018
19
Irritable bowel syndrome and functional dyspepsia: what can epidemiology tell us about etiology? ( 29774764 )
2018
20
Increased prevalence of rare sucrase-isomaltase (SI) pathogenic variants in irritable bowel syndrome patients. ( 29408290 )
2018
21
The Emerging Role of Mast Cells in Irritable Bowel Syndrome. ( 29942225 )
2018
22
Altered Intestinal Microbiota with Increased Abundance of <i>Prevotella</i> Is Associated with High Risk of Diarrhea-Predominant Irritable Bowel Syndrome. ( 29967640 )
2018
23
Sensitive bowel syndrome better than irritable bowel syndrome. ( 29426620 )
2018
24
Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis. ( 29977312 )
2018
25
Research Design Characteristics of Published Pharmacologic Randomized Clinical Trials for Irritable Bowel Syndrome and Chronic Pelvic Pain Conditions: an Acttion Systemic Review. ( 29412183 )
2018
26
Relationship between sympathoadrenal and pituitary-adrenal response during colorectal distention in the presence of corticotropin-releasing hormone in patients with irritable bowel syndrome and healthy controls. ( 29979696 )
2018
27
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. ( 29950604 )
2018
28
Heat shock protein 70 protects mouse against post-infection irritable bowel syndrome via up-regulating intestinal I^I' T cell's Th17 response. ( 29928498 )
2018
29
High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment. ( 29977339 )
2018
30
Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. ( 29946799 )
2018
31
Efficacy and safety of Modified Tongxie Yaofang in diarrhea-predominant irritable bowel syndrome management: A meta-analysis of randomized, positive medicine-controlled trials. ( 29408906 )
2018
32
Comparison of Lactase Variant MCM6 -13910 C&amp;gt;T Testing and Self-report of Dairy Sensitivity in Patients With Irritable Bowel Syndrome. ( 29912753 )
2018
33
The importance of cluster analysis for enhancing clinical practice: an example from irritable bowel syndrome. ( 29447026 )
2018
34
Characteristics of the bacterial microbiome in association with common intestinal parasites in irritable bowel syndrome. ( 29915224 )
2018
35
Patients with primary restless legs syndrome have higher prevalence of autonomic dysfunction and irritable bowel syndrome. ( 29372261 )
2018
36
G protein beta 3(<i>GNI^3</i>) C825T polymorphism and irritable bowel syndrome susceptibility: an updated meta-analysis based on eleven case-control studies. ( 29416810 )
2018
37
Additional Glance on the Role of <i>Dientamoeba fragilis</i> &amp;amp; <i>Blastocystis hominis</i> in Patients with Irritable Bowel Syndrome. ( 29963091 )
2018
38
Chronic abdominal pain in irritable bowel syndrome - current and future therapies. ( 29957084 )
2018
39
Effect of<i>Lactobacillus rhamnosus</i>GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome. ( 29391756 )
2018
40
Gut Microbiota-Based Therapies for Irritable Bowel Syndrome. ( 29446765 )
2018
41
Advancements in drug development for diarrhea-predominant irritable bowel syndrome. ( 29451407 )
2018
42
Prevalence of sleep disorder in irritable bowel syndrome: A systematic review with meta-analysis. ( 29652034 )
2018
43
The prevalence of celiac disease in adult Chinese patients with diarrhea predominant irritable bowel syndrome of China, a prospective, controlled, cohort study. ( 29451364 )
2018
44
Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. ( 29980607 )
2018
45
The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. ( 29684865 )
2018
46
To Understand the Modulatory Effect of Probiotics on Irritable Bowel Syndrome. ( 29955019 )
2018
47
Key mechanisms of cognitive behavioural therapy in irritable bowel syndrome: The importance of gastrointestinal related cognitions, behaviours and general anxiety. ( 30522750 )
2018
48
A Comparison of the Prevalence of Anxiety and Depression Between Uncomplicated and Complex IBD Patient Groups. ( 30272605 )
2018
49
A Case of IBD Immunosuppression Related Salmonella Aortitis Requiring Emergency Vascular Grafting. ( 30395221 )
2018
50
Should we set-up routine screening for primary sclerosing cholangitis in all IBD patients? ( 30274792 )
2018

Variations for Irritable Bowel Syndrome

Expression for Irritable Bowel Syndrome

Search GEO for disease gene expression data for Irritable Bowel Syndrome.

Pathways for Irritable Bowel Syndrome

GO Terms for Irritable Bowel Syndrome

Sources for Irritable Bowel Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....